Today, Totient, an AI-driven drug discovery company based in Cambridge, MA, emerged from stealth with $10M in seed funding and a strategic discovery partnership for COVID-19.

Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. Totient uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble the most potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses. For more information, visit www.totient.bio. 

Totient Comes Out of Stealth with Novel COVID-19 Program and $10M in Seed Funding for AI-Driven Drug Discovery Platform

Description

Company Information

Funding Insights

Totient Comes Out of Stealth with Novel COVID-19 Program and $10M in Seed Funding for AI-Driven Drug Discovery Platform

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information